Shots:
- Unnatural Products (UNP) & argenx have entered into a strategic multi-target research collaboration to identify & develop oral macrocyclic peptide drugs for hard-to-target diseases leveraging UNP’s drug discovery platform
- As per the deal, UNP will receive upfront payment, equity investment, near-term, & R&D payments, plus ~$1.5B in research, development, regulatory, & commercial milestones as well as option payments, with net sales-based tiered royalties
- UNP will conduct R&D until IND-enabling studies to develop the macrocyclic peptides for targets identified by argenx, which will hold an exclusive option to develop & commercialize products for these targets across multiple indications
Ref: GlobeNewswire | Image: Unnatural Products & Argenx | Press Release
Related News:- Neurocrine Biosciences Initiates P-I Study of NBIP-01435 to Treat CAH
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
